Cytosorbents (NASDAQ:CTSO) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note released on Wednesday. The firm issued a hold rating on the medical research company’s stock.

Separately, HC Wainwright reaffirmed a neutral rating and issued a $1.00 price objective on shares of Cytosorbents in a research note on Friday, March 15th.

Cytosorbents Stock Performance

NASDAQ CTSO opened at $0.82 on Wednesday. The stock has a market capitalization of $44.63 million, a PE ratio of -1.28 and a beta of 0.58. Cytosorbents has a 1-year low of $0.78 and a 1-year high of $4.29. The business has a 50 day simple moving average of $0.94 and a two-hundred day simple moving average of $1.17. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.77 and a quick ratio of 1.51.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings data on Thursday, March 14th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.02. The business had revenue of $8.67 million during the quarter, compared to analyst estimates of $9.29 million. Cytosorbents had a negative return on equity of 120.24% and a negative net margin of 78.43%. On average, research analysts predict that Cytosorbents will post -0.36 EPS for the current fiscal year.

Institutional Investors Weigh In On Cytosorbents

A number of institutional investors and hedge funds have recently modified their holdings of CTSO. Avenir Corp lifted its stake in shares of Cytosorbents by 12.3% during the 4th quarter. Avenir Corp now owns 3,051,402 shares of the medical research company’s stock worth $3,387,000 after acquiring an additional 334,005 shares during the last quarter. Skylands Capital LLC lifted its stake in shares of Cytosorbents by 10.5% during the 4th quarter. Skylands Capital LLC now owns 3,254,213 shares of the medical research company’s stock worth $3,612,000 after acquiring an additional 309,543 shares during the last quarter. Neuberger Berman Group LLC lifted its stake in shares of Cytosorbents by 19.9% during the 4th quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock worth $1,997,000 after acquiring an additional 299,103 shares during the last quarter. Sargent Investment Group LLC lifted its stake in shares of Cytosorbents by 4.1% during the 4th quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock worth $1,453,000 after acquiring an additional 51,699 shares during the last quarter. Finally, Raymond James & Associates bought a new stake in shares of Cytosorbents during the 4th quarter worth approximately $56,000. 32.87% of the stock is owned by institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.